Atara Biotherapeutics (ATRA) Retained Earnings (2013 - 2026)

Atara Biotherapeutics has reported Retained Earnings for 14 years, with the latest figure at -$2.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings changed 0.47% year-over-year to -$2.0 billion; the trailing twelve-month figure through Mar 2026 stood at -$2.0 billion (changed 0.47% YoY), and the FY2025 full-year result was -$2.0 billion, down 25273412.5% from the prior year.
• Retained Earnings for Q1 2026 stood at -$2.0 billion, roughly flat from -$2.0 billion in the prior quarter.
• The five-year high for Retained Earnings was $8000.0 in Q4 2024, with the low at -$2.0 billion in Q3 2024.
• Historically, Retained Earnings has averaged -$1.4 billion across 5 years, with a median of -$1.9 billion in 2023.
• Annual changes were most pronounced in 2024 — Retained Earnings jumped 100.0% — and 2025, when it tumbled 25273412.5%.
• Atara Biotherapeutics' Retained Earnings stood at -$1.7 billion in 2022, then decreased by 16.31% to -$2.0 billion in 2023, then jumped by 100.0% to $8000.0 in 2024, then plunged by 25273412.5% to -$2.0 billion in 2025, then fell by 0.21% to -$2.0 billion in 2026.
• The last three Retained Earnings figures came in at -$2.0 billion (Q1 2026), -$2.0 billion (Q4 2025), and -$2.0 billion (Q3 2025), per Business Quant data.